SAB Biotherapeutics (NASDAQ:SABS) Issues Quarterly Earnings Results

SAB Biotherapeutics (NASDAQ:SABS) released its quarterly earnings data on Thursday. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Price Performance

Shares of SABS stock traded up $0.05 during trading hours on Friday, hitting $3.90. 343,103 shares of the company’s stock were exchanged, compared to its average volume of 495,972. SAB Biotherapeutics has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The firm has a market cap of $298.19 million, a P/E ratio of -3.00 and a beta of 0.53. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $3.68 and a two-hundred day moving average of $3.83.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the third quarter valued at $30,000. Dimensional Fund Advisors LP purchased a new position in SAB Biotherapeutics in the 3rd quarter valued at about $32,000. State of Wyoming purchased a new position in SAB Biotherapeutics in the 4th quarter valued at about $34,000. Virtu Financial LLC acquired a new stake in SAB Biotherapeutics in the 3rd quarter worth about $40,000. Finally, State Street Corp purchased a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $49,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics News Summary

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Brookline raised its earnings outlook. The firm improved its Q3 and Q4 2026 EPS forecasts to $(0.24) from $(0.25), raised its FY2027 estimate to $(0.95) from $(1.07), and lifted FY2028 to $(0.95) from $(1.17). Most notably, Brookline shifted its FY2029 forecast to positive EPS of $0.48 from a prior loss estimate of $(0.79), and raised its FY2030 forecast to $1.38 from $1.17. These revisions suggest stronger expected profitability over the longer term. MarketBeat SAB Biotherapeutics analyst estimates
• Positive Sentiment: HC Wainwright retained its Buy rating and $10 price target. The target implies substantial upside from recent trading levels, potentially supporting investor interest despite the firm’s lower earnings forecasts. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Analyst views remain divided. Brookline’s upgrades contrast with HC Wainwright’s reductions, making the overall earnings signal mixed. The consensus forecast remains a loss of approximately $(1.19) per share for the current year.
• Negative Sentiment: HC Wainwright lowered several forecasts. The firm cut Q3 2026 EPS to $(0.29) from $(0.26), Q4 to $(0.31) from $(0.27), and FY2026 to $(1.21) from $(1.10). It also reduced FY2027 through FY2030 estimates, indicating that losses may persist longer than previously expected. HC Wainwright SAB Biotherapeutics estimates

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Chardan Capital upped their target price on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Jefferies Financial Group assumed coverage on SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price target for the company. Wall Street Zen lowered SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, August 2nd. Weiss Ratings cut shares of SAB Biotherapeutics from a “sell (d+)” rating to a “sell (e+)” rating in a research note on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a report on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.